Scarica l'app Stockscreener
198.94
0.38%
-0.76
Dopo l'orario di chiusura:
198.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$199.70
Aprire:
$200.98
Volume 24 ore:
777.14K
Relative Volume:
0.80
Capitalizzazione di mercato:
$21.86B
Reddito:
$11.04B
Utile/perdita netta:
$1.04B
Rapporto P/E:
22.70
EPS:
8.7626
Flusso di cassa netto:
$1.36B
1 W Prestazione:
-1.31%
1M Prestazione:
-3.83%
6M Prestazione:
+10.42%
1 anno Prestazione:
+16.91%
Intervallo 1D:
$198.86
$201.88
Intervallo di 1 settimana:
$198.37
$205.00
Portata 52W:
$157.20
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
198.94 | 21.94B | 11.04B | 1.04B | 1.36B | 8.7626 |
|
TMO
Thermo Fisher Scientific Inc
|
470.00 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
191.39 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
586.37 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.83 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
290.02 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics (DGX) down 4.2% since last earnings report: Can it rebound? - MSN
Aquatic Capital Management LLC Has $8.06 Million Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
EdgePoint Investment Group Inc. Grows Position in Quest Diagnostics Incorporated $DGX - MarketBeat
CSM Advisors LLC Sells 20,078 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Crawford Investment Counsel Inc. Purchases 9,473 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Position Increased by 8 Knots Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Sees Large Decrease in Short Interest - MarketBeat
iSAM Funds UK Ltd Invests $1.47 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Wentworth to Board of Directors - New Jersey Business Magazine
Korea Investment CORP Sells 14,900 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Former Walgreens Boots Alliance CEO Timothy Wentworth to Board of Directors - Minichart
Quest Diagnostics (DGX) Appoints Timothy Wentworth to Board of D - GuruFocus
Quest Diagnostics adds ex-Walgreens CEO to board - Investing.com South Africa
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors - Quest Diagnostics Newsroom
Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Quest Diagnostics Incorporated $DGX Position Trimmed by Schroder Investment Management Group - MarketBeat
Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test - simplywall.st
First Trust Advisors LP Raises Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Banque Cantonale Vaudoise Acquires 5,985 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Should You Keep DGX Shares in Your Investment Portfolio? - Bitget
Should You Continue to Hold DGX Stock in Your Portfolio? - The Globe and Mail
Barclays PLC Has $47.86 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Implied volatility surging for Quest Diagnostics stock options - MSN
Insider Selling: Quest Diagnostics (NYSE:DGX) EVP Sells $1,146,115.18 in Stock - MarketBeat
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 3,878 Shares of Stock - MarketBeat
Plewman Patrick, Quest Diagnostics SVP, sells $588k in stock - Investing.com Nigeria
Plewman Patrick, Quest Diagnostics SVP, sells $588k in stock By Investing.com - Investing.com Australia
Quest Diagnostics Insider Sold Shares Worth $799,682, According to a Recent SEC Filing - marketscreener.com
Quest Diagnostics (DGX) SVP awarded 5,682 shares; 2,326 withheld for taxes - Stock Titan
Quest Diagnostics (DGX) SVP & General Counsel reports award, tax withholding and 10b5-1 share sale - Stock Titan
Quest Diagnostics (DGX) CEO receives stock award and uses shares for taxes - Stock Titan
Quest Diagnostics (DGX) SVP granted 6,200 shares, surrenders 2,628 for taxes - Stock Titan
Dimensional Fund Advisors LP Has $363.51 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Implied Volatility Surging for Quest Diagnostics Stock Options - TradingView
Genomics Services Market Projected to Surpass USD 25.18 Billion by 2035; Increasing Genetic Disorders’ Prevalence is Driving Market Growth Globally – SNS Insider - GlobeNewswire Inc.
Elo Mutual Pension Insurance Co Makes New $2.03 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE: DGX) EVP sells shares and disposes stock for taxes - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP sells 526 shares in plan - Stock Titan
Quest Diagnostics (NYSE: DGX) CEO discloses 10,000-share stock sale - Stock Titan
Quest Diagnostics (DGX) SVP sells and withholds shares under plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP covers tax obligations with share sale - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports tax-withholding stock disposition on Form 4 - Stock Titan
Quest Diagnostics Hits New 52-Week High of $213.50, Up 49.79% - Markets Mojo
Quest Diagnostics Remains a Dominant Competitor in Independent Labs - Morningstar
Quest Diagnostics Incorporated (NYSE:DGX) Short Interest Update - MarketBeat
Catherine Doherty reports 27,598 DGX share dispositions in Form 144 (NYSE: DGX) - Stock Titan
DGX insider sale notice (DGX) — 526 vested shares; prior 1,111 sold - Stock Titan
Insider sale notice for DGX (DGX): Plewman lists proposed share disposals - Stock Titan
Victory Capital Management Inc. Sells 465,252 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
DGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):